Want to see HK:2257 full AI Analyst Report?
2257 Stock Chart & Stats
HK$3.75
HK$0.00(0.00%)
At close: 4:00 PM EDT
HK$3.75
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$3.55 - HK$15.80
Previous CloseN/A
Volume54.85K
Average Volume (3M)49.83K
Market Cap
HK$412.74M
Enterprise ValueHK$479.99
Total Cash (Recent Filing)HK$7.19M
Total Debt (Recent Filing)HK$25.26M
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding112,157,135
10 Day Avg. Volume41,300
30 Day Avg. Volume49,828
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-9.39
Price to Sales (P/S)0.00
P/FCF Ratio-10.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)HK$162.00M
Bulls Say, Bears Say
Bulls Say
Specialized RNAi Therapeutics PlatformA focused RNAi platform gives Sirnaomics a specialized technology base in a potentially important therapeutic modality, supporting differentiated research capabilities and the possibility of building value through successful clinical development.
Improving Losses And Cash BurnThe improvement in annual losses and cash usage indicates some progress in cost control and resource allocation. If sustained, this could extend operational runway and reduce the pace of future funding needs, despite continued cash consumption.
Positive EPS GrowthReported positive EPS growth suggests the earnings trajectory improved from a very weak base. Continued progress in reducing per-share losses could strengthen financing credibility and provide a better foundation for future clinical and commercial investment.
Bears Say
No Current Revenue ScaleZero revenue highlights the absence of a reliable commercial base and leaves the company dependent on clinical progress, partnerships, or external financing. Limited scale also makes fixed research and development costs harder to absorb.
Negative Shareholder EquityNegative equity materially reduces balance-sheet flexibility and raises refinancing and dilution risk. With assets also shrinking, Sirnaomics has less financial capacity to absorb setbacks or fund its pipeline without additional capital.
Persistent Cash BurnThe business remains unable to fund operations internally, as losses continue to translate into cash outflows. Persistent negative free cash flow increases dependence on financing and could constrain the pace of research, trials, and commercialization.
Sirnaomics Ltd. News
2257 FAQ
What was Sirnaomics Ltd.’s price range in the past 12 months?
Sirnaomics Ltd. lowest stock price was HK$3.55 and its highest was HK$15.80 in the past 12 months.
What is Sirnaomics Ltd.’s market cap?
Sirnaomics Ltd.’s market cap is HK$412.74M.
When is Sirnaomics Ltd.’s upcoming earnings report date?
Sirnaomics Ltd.’s upcoming earnings report date is Apr 01, 2027 which is in 189 days.
How were Sirnaomics Ltd.’s earnings last quarter?
Sirnaomics Ltd. released its earnings results on Aug 28, 2026. The company reported HK$0.007 earnings per share for the quarter.
Is Sirnaomics Ltd. overvalued?
According to Wall Street analysts Sirnaomics Ltd.’s price is currently Overvalued.
Does Sirnaomics Ltd. pay dividends?
Sirnaomics Ltd. does not currently pay dividends.
What is Sirnaomics Ltd.’s EPS estimate?
Sirnaomics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sirnaomics Ltd. have?
Sirnaomics Ltd. has 112,157,135 shares outstanding.
What happened to Sirnaomics Ltd.’s price movement after its last earnings report?
Sirnaomics Ltd. reported an EPS of HK$0.007 in its last earnings report. Following the earnings report the stock price went down -1.25%.
Which hedge fund is a major shareholder of Sirnaomics Ltd.?
Currently, no hedge funds are holding shares in HK:2257
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sirnaomics Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-37.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Sirnaomics Ltd.
Sirnaomics Ltd. is an RNA therapeutics biopharmaceutical company, founded in 2007 and headquartered in Gaithersburg, Maryland. The company is dedicated to identifying and developing innovative therapeutic compounds aimed at addressing significant medical needs across the United States and the People's Republic of China. Its leading pipeline assets include STP705, which is being investigated for conditions such as cutaneous squamous cell carcinoma in situ, basal cell carcinoma, various liver-related cancers (cholangiocarcinoma, hepatocellular carcinoma, liver metastases), as well as for keloid scar remodeling, hypertrophic scarring, and fat sculpting. Another prominent candidate, STP707, is designed to treat cholangiocarcinoma, hepatocellular carcinoma, liver metastases, metastatic cutaneous squamous cell carcinoma, non-small cell lung cancer, and both liver and lung fibrosis. Beyond these lead programs, Sirnaomics is advancing STP355 for a range of cancers; STP369 for head and neck/bladder cancers; STP779 for liver, lung, and pancreatic cancers; and STP902 for breast cancer. The company's portfolio also extends to infectious diseases with STP702 for influenza, STP908 for COVID-19, the RIM730 COVID-19 vaccine, and STP909 for HPV/cervical cancer. Furthermore, its developmental pipeline encompasses STP122G for thrombotic disorders, STP125G for hypertriglyceridemia, STP144G for complement-mediated ailments, STP133G for cardiometabolic conditions, and STP155G for hepatitis B virus.
Technical Analysis
Alphamab Oncology
―
Jacobio Pharmaceuticals Group Co., Ltd.
―
CARsgen Therapeutics Holdings Ltd.
―
Transcenta Holding Limited
―
Ascentage Pharma Group International
―